Login to Your Account



BioLineRx Expands Pipeline, Pursues Oral HCV Treatment

By Marie Powers
Staff Writer

Wednesday, January 25, 2012

Another hepatitis C candidate knocked the socks off investors Tuesday as Jerusalem's BioLineRx Ltd. added a new prong to its pipeline, inking a worldwide, exclusive license agreement with the French firm Genoscience to develop and commercialize the orally available protease inhibitor (PI) BL-8020.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription